US Stock MarketDetailed Quotes
ALGS Aligos Therapeutics
- 25.510
- +2.520+10.96%
Close Nov 29 13:00 ET
- 26.150
- +0.640+2.51%
Post 17:01 ET
91.53MMarket Cap-3518P/E (TTM)
25.510High23.000Low399.64KVolume23.425Open22.990Pre Close9.82MTurnover22.03%Turnover RatioLossP/E (Static)3.59MShares30.00052wk High1.83P/B46.28MFloat Cap6.76052wk Low--Dividend TTM1.81MShs Float937.748Historical High--Div YieldTTM10.92%Amplitude6.760Historical Low24.582Avg Price1Lot Size
About Aligos Therapeutics Company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Company Profile
SymbolALGS
Company NameAligos Therapeutics
Listing DateOct 16, 2020
Issue Price15.00
Founded2018
CEODr. Lawrence M. Blatt,PhD
MarketNASDAQ
Employees66
Fiscal Year Ends12-31
Address1 Corporate Drive,2nd floor
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-800-466-6059
Websitehttp://www.aligos.com
Company Executives
- Name
- Position
- Salary
- Dr. Lawrence M. Blatt,PhD
- President, Chairman of the Board and Chief Executive Officer
- 1.34M
- Lesley Ann Calhoun
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Julian A. Symons, D.Phil.
- Executive Vice President and Chief Scientific Officer
- 836.32K
- Dr. Heather Elizabeth Preston, M.D.
- Director
- --
- Margarita Chavez, J.D.
- Director
- --
- James Scopa
- Independent Director
- 67.90K
- Dr. K. Peter Hirth, PhD
- Independent Director
- 60.40K
- Dr. Bridget A. Martell, M.D.
- Independent Director
- 52.90K
- Carole L. Nuechterlein, J.D.
- Independent Director
- 12.90K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
